转化医学电子杂志
轉化醫學電子雜誌
전화의학전자잡지
E-Journal of Translational Medicine
2015年
9期
34-37
,共4页
王轶珊%赵荣%李云霞%毕清
王軼珊%趙榮%李雲霞%畢清
왕질산%조영%리운하%필청
乳腺癌%化疗%不良反应
乳腺癌%化療%不良反應
유선암%화료%불량반응
breast cancer%chemotherapy%adverse reaction
目的:分析乳腺癌术后化疗常见不良反应的临床特点. 方法:选取我院2011-01/2014-01收治的经手术治疗后存在浸润性乳腺癌的68例患者,按照随机数表法分为观察组和对照组. 观察组患者采用AC→T方案化疗,对照组采用TAC方案化疗. 比较两组患者化疗前1d与化疗后7d免疫功能、血象及细胞因子水平的变化. 观察两组患者化疗后的不良反应及其临床特点. 结果:化疗后,观察组患者的 CD4+( 43. 22 ± 2.76)%、CD8+(42.45±4.32)%、CD4+/CD8+(1.96±0.35)水平明显高于对照组(P<0.05). 观察组患者的免疫球蛋白 IgA、IgG、IgM水平分别为(1.25±0.11)g/L、(8.21±1.22)g/L、(1.24± 0.21)g/L明显低于对照组(P<0.05). 观察组患者的 PLT、WBC、IL-4、IL-10水平分别为(175±24)×109/L、(8.43±2.42)× 109/L、(46.32±4.22)U/mL、(34.21±4.21)U/mL,明显高于对照组. 观察组患者的中性粒细胞减少率与减少性的中性粒细胞发热的不良反应率分别为44. 12%、26. 47%,明显低于对照组( P<0.05) ,但两组患者在水钠潴留、外周神经毒性、皮肤指甲改变及过敏等不良反应方面比较,差异无统计学意义(P>0.05) . 结论:乳腺癌术后患者采取不同化疗方案均存在不良反应,然而大多数为Ⅲ度以下的不良反应,均能耐受,予以有效处理后,不良反应有所好转.
目的:分析乳腺癌術後化療常見不良反應的臨床特點. 方法:選取我院2011-01/2014-01收治的經手術治療後存在浸潤性乳腺癌的68例患者,按照隨機數錶法分為觀察組和對照組. 觀察組患者採用AC→T方案化療,對照組採用TAC方案化療. 比較兩組患者化療前1d與化療後7d免疫功能、血象及細胞因子水平的變化. 觀察兩組患者化療後的不良反應及其臨床特點. 結果:化療後,觀察組患者的 CD4+( 43. 22 ± 2.76)%、CD8+(42.45±4.32)%、CD4+/CD8+(1.96±0.35)水平明顯高于對照組(P<0.05). 觀察組患者的免疫毬蛋白 IgA、IgG、IgM水平分彆為(1.25±0.11)g/L、(8.21±1.22)g/L、(1.24± 0.21)g/L明顯低于對照組(P<0.05). 觀察組患者的 PLT、WBC、IL-4、IL-10水平分彆為(175±24)×109/L、(8.43±2.42)× 109/L、(46.32±4.22)U/mL、(34.21±4.21)U/mL,明顯高于對照組. 觀察組患者的中性粒細胞減少率與減少性的中性粒細胞髮熱的不良反應率分彆為44. 12%、26. 47%,明顯低于對照組( P<0.05) ,但兩組患者在水鈉潴留、外週神經毒性、皮膚指甲改變及過敏等不良反應方麵比較,差異無統計學意義(P>0.05) . 結論:乳腺癌術後患者採取不同化療方案均存在不良反應,然而大多數為Ⅲ度以下的不良反應,均能耐受,予以有效處理後,不良反應有所好轉.
목적:분석유선암술후화료상견불량반응적림상특점. 방법:선취아원2011-01/2014-01수치적경수술치료후존재침윤성유선암적68례환자,안조수궤수표법분위관찰조화대조조. 관찰조환자채용AC→T방안화료,대조조채용TAC방안화료. 비교량조환자화료전1d여화료후7d면역공능、혈상급세포인자수평적변화. 관찰량조환자화료후적불량반응급기림상특점. 결과:화료후,관찰조환자적 CD4+( 43. 22 ± 2.76)%、CD8+(42.45±4.32)%、CD4+/CD8+(1.96±0.35)수평명현고우대조조(P<0.05). 관찰조환자적면역구단백 IgA、IgG、IgM수평분별위(1.25±0.11)g/L、(8.21±1.22)g/L、(1.24± 0.21)g/L명현저우대조조(P<0.05). 관찰조환자적 PLT、WBC、IL-4、IL-10수평분별위(175±24)×109/L、(8.43±2.42)× 109/L、(46.32±4.22)U/mL、(34.21±4.21)U/mL,명현고우대조조. 관찰조환자적중성립세포감소솔여감소성적중성립세포발열적불량반응솔분별위44. 12%、26. 47%,명현저우대조조( P<0.05) ,단량조환자재수납저류、외주신경독성、피부지갑개변급과민등불량반응방면비교,차이무통계학의의(P>0.05) . 결론:유선암술후환자채취불동화료방안균존재불량반응,연이대다수위Ⅲ도이하적불량반응,균능내수,여이유효처리후,불량반응유소호전.
AIM: To analyze the clinical characteristics of common adverse reactions of breast cancer after chemotherapy. METHODS:A total of 68 cases of patients with invasive breast cancer after operation, admitted into our hospital from January 2011 to January 2014, were randomly divided into observation group and control group. The observation group received AC→T chemotherapy, while, the control group performed TAC chemo-therapy. The immune function, blood and cytokine level changes in 1 day before chemotherapy 7 days after chemotherapy were compared. At the same time, the adverse reactions and clinical characteristics of the two groups of patients after chemotherapy were observed. RESULTS: After chemotherapy, the level of CD4+[ (43.22±2.76)%], CD8+[(42.45±4.32)%], CD4+/CD8+[(1.96±0.35)] in the observation group were significantly higher than that of the control group (P<0.05). IgA, IgG, IgM levels of the observation group were respectively (1.25±0.11) g/L, (8.21±1.22) g/L, (1.24±0.21) g/L, which were significantly lower than those of the control group ( P<0.05 ) . And the level of PLT, WBC, IL-4, IL-10 in observation group were (175±24) × 109/L, (8.43±2.42)×109/L, (46.32±4.22) U/mL, (34.21±4.21) U/mL, which were significantly higher than the control group. The rate of neutropenia and fever adverse reaction of neutropenia respectively were 44. 12% and 26. 47%, which were significantly lower than that of the control group ( P<0.05) , but the water-so-dium retention, peripheral neurotoxicity, nail changes and skin allergic reactions and other adverse reactions of two groups had no statistioncally significant difference (P>0.05). CONCLUSION:The breast cancer patients taking chemotherapy are presenting different adverse reactions, but most of the adverse reactions were below the level of Ⅲ that patients can tolerate, and the adverse reaction will be improved with effective management.
